Senior Editor – Europe
Latest From David Ridley
HBW Insight talks to Numan's chief medical strategy officer Professor Sam Shah about how the UK tech start-up is bringing innovation to the country's men's health category.
[Link Fixed] Australia's Ministry of Health has provisionally switched CBD from prescription-only to OTC status to widen access in the absence of any safety concerns and to encourage companies to undertake much-needed clinical trials to prove efficacy for CBD in low doses. However, switch expert Natalie Gauld thinks these expensive trials, and therefore approved Australian OTC CBD products, may not be forthcoming.
Bayer Consumer Care matches Rennie with popular dating app Tinder in the UK for an innovative new digital marketing campaign, which uses "branded profile cards" to drive engagement with the firm's flagship heartburn brand.
Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal.
Germany's Expert Committee for Prescription will consider the reverse-switch of tyrothricin – a key ingredient in Stada's recently-acquired Lemocin throat lozenge – to presciption-only status and the Rx-to-OTC switch of soluble fluoride tablets for the oral treatment of osteoporosis.
Sanofi Consumer Health Care leans into probiotics trend with another UK probiotic supplement, DioraByota.